Trial Search Results

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Other: laboratory biomarker analysis


Inclusion Criteria:

   - Newly diagnosed acute lymphoblastic leukemia, defined by any of the following:

      - At least 25% blasts in the bone marrow

      - Absolute blast count at least 10,000/mm^3, if bone marrow aspiration is not

   - No prior registration on this study

Ages Eligible for Study

1 Year - 30 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
Not Recruiting